ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2538

Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease

Rafael Gálvez Sánchez1, José Luis Martín-Varillas2, Lara Sánchez Bilbao3, Ivan Ferraz Amaro4, Carmen Lasa Teja5, Elena Aurrecoechea6, Diana Prieto-Peña7 and Ricardo Blanco3, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 2Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, 3Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 6Hospital Sierrallana, CANTABRIA, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Behçet's Syndrome, classification criteria, Outcome measures, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision of the International Criteria for BD (ITR-ICBD)are based on a scoring system. Our aim was to assess a) the sensitivity and b) the concordance between ISG and the ICDB criteria in global and severe ocular, vascular and neurological) BD.

Methods: Patients diagnosed with BD by expert rheumatologists in a well-defined population in Northern Spain between January 1980-November 2023 were studied. Both ISG and ICBD criteria were compared. Sensitivity and concordance were evaluated using two statistical methods: the Prevalence-Adjusted and Bias-Adjusted Kappa (PABAK), which accounts for the effects of prevalence and bias, and the unadjusted Cohen’s Kappa coefficient.

Results: We studied 142 patients diagnosed with BD by expert rheumatologists (73 men, mean age: 36.4±13.9 years). Among them, 84 fulfilled the ISG criteria and 116 met the ICBD criteria, figure 1 shows the overlap between expert diagnosis and the two classification systems. a) The sensitivity of the ISG and ICBD criteria in the overall cohort was 59.1% and 81.6%, respectively. Among patients with severe manifestations (ocular, vascular, or neurological), sensitivity increased to 71.2% for ISG and 92.5% for ICBD as shown in figure 2. b) The overall concordance between the two criteria was moderate, with a Kappa of 0.490 (95% CI: 0.356–0.623), and 70.4% of patients classified identically. When adjusting for prevalence and bias, concordance improved slightly (PABAK = 0.549). The highest agreement between classification criteria was observed when ocular involvement was deliberately added to all patients in the cohort (PABAK = 0.788; Kappa = 0.405), whereas the lowest agreement occurred when vascular involvement was added (PABAK = 0.338; Kappa = 0.216) (figure 3).

Conclusion: Sensitivity of the ICBD criteria was higher than the traditional ISG criteria in classifying BD, particularly in severe cases. Greater differences in concordance between both diagnostic criteria for BD were found when modifying the ocular involvement variable.

Supporting image 1Figure 1: Overlap of Behçet’s Disease cases detected by Expert Diagnosis, ICBD, and ISG criteria. The Venn diagram shows the unique and shared cases among the three methods.

Supporting image 2Figure 2: Comparison of ISG and ICBD classification criteria performance in Behçet’s Disease.

Supporting image 3Figure 3. Variation in concordance between ISG and ICBD classification criteria when each severe manifestation is systematically added to or removed from all 142 patients.


Disclosures: R. Gálvez Sánchez: None; J. Martín-Varillas: AbbVie, Pfizer, Lilly, Celgene, Janssen, and UCB Pharma, 5; L. Sánchez Bilbao: AbbVie/Abbott, 6, Eli Lilly, 6, Janssen, 6, UCB, 6; I. Ferraz Amaro: None; C. Lasa Teja: None; E. Aurrecoechea: None; D. Prieto-Peña: None; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Gálvez Sánchez R, Martín-Varillas J, Sánchez Bilbao L, Ferraz Amaro I, Lasa Teja C, Aurrecoechea E, Prieto-Peña D, Blanco R. Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/comparative-study-of-two-classification-criteria-sets-in-real-clinical-practice-in-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-study-of-two-classification-criteria-sets-in-real-clinical-practice-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology